Study Details
Dose escalation study to investigate the safety, tolerability and pharmacokinetics of ASP2215 in Japanese patients with relapsed or refractory acute myeloid leukemia
Clinicaltrials.gov ID
Astellas Study ID
2215-CL-0102
EudraCT ID
N/A
Condition
Leukemia - AML
Phase
Phase 1
Age
18 years - N/A
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Jun 2014 - Jun 2016
Masking
None (Open Label)
Enrollment number
24
A Phase 1 Open-label, Dose-escalation Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Dose escalation study to investigate the safety, tolerability and pharmacokinetics of ASP2215 in Japanese patients with relapsed or refractory acute myeloid leukemia? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site JP00001
Gunma, Japan
Site JP00004
Tokyo, Japan
Site JP00003
Fukuoka, Japan
Site JP00002
Aichi, Japan
Site JP00005
Tokyo, Japan